ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma by unknown
Brief Definitive Report 
ras  ONCOGENE  p21  EXPRESSION  IS  INCREASED 
IN  PREMALIGNANT  LESIONS  AND  HIGH  GRADE 
BLADDER  CARCINOMA 
BY  MICHAEL V.  VIOLA,  FRANK  FROMOWITZ, SHEILA ORAVEZ, 
SWATI  DEB,  AND JEFFREY  SCHLOM* 
From the Departments of Medicine, Microbiology  and Pathology,  State University  of New York 
at Stony Brook, Stony Brook, New York 11794, and the *Tumor Immunology and Biology 
Branch, National Cancer Institute, National Institutes of  Health, Bethesda, Maryland 20205 
The most frequently detected transformation-inducing genes in human solid 
tumors are members of the ras family of cellular oncogenes (1). Somatic muta- 
tions of the cellular ras oncogenes result in a gene product (p21) with increased 
transformation-inducing activity (2-4).  Quantitative changes in  ras  expression 
may be  equally important in  carcinogenesis, since  increased  levels of cellular 
Harvey ras (c-H-ras) p21  will transform cells in vitro (5), and increased levels of 
messenger RNA (mRNA) specific for ras genes, as well as other oncogenes, are 
frequently detected in human tumors (6). However, there is a paucity of data on 
the relationship between the malignant potential of a  tumor and the levels of 
p21 expressed in neoplastic cells (7). Human bladder cancer is particularly suited 
for studies of this sort, since patients with this disease have diffuse abnormalities 
of the urinary tract epithelium (urothelium) consisting of benign and presumed 
"premalignant" (dysplastic) lesions in regions separate from the primary carci- 
noma (8). We have used an immunohistochemical assay to localize and quantitate 
ras p21  in the urinary tract of bladder cancer patients. In contrast to previous 
studies (9,  10) showing ras activation (mutation) in < 10% of bladder carcinomas, 
our study demonstrates increased ras p21  expression in all high grade bladder 
carcinomas  studied,  and,  further,  this  antigen  may  be  an  indicator  of  the 
malignant potential of premalignant as well as neoplastic lesions of the bladder. 
Materials and Methods 
Pathological Classification.  The criteria of the National Bladder Cancer Collaborative 
Group A were  used  to classify benign  (hyperplasia) and dysplastic (atypical) epithelial 
changes (11). Papillary and invasive carcinomas of the bladder were classified according 
to the degree of nuclear anaplasia (12). Patients  who had received  previous  bladder 
radiation or chemotherapy were excluded from the study. 
Immunoperoxidase Studies.  The ras p21  monoclonal antibody (RAP-5) was generated 
against a synthetic peptide having the sequence of amino acids 10-17 of the T24 bladder 
cancer cell line H-ras-1 oncogene. This peptide (Gly, Ala, Val, Gly, Val, Gly, Lys, Ser) has 
a Gly --0 Val substitution  in position  12, compared to the normal cellular H-ras-I  p21. 
The specificity of RAP-5 for ras  p21  was established  by protein blot (Western) and 
radioimmunoassay experiments,  and was reported previously (13). This antibody reacts 
with both the normal human cellular  Harvey,  Kirsten (K), and neuroblastoma  (N) ras 
p21, as well as with p21  molecules with a substitution at residue  12, e.g. T24 H-ras, v-H- 
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ras, v-K-ras (ref.  13 and unpublished results). The avidin-biotin complex immunoperoxi- 
dase assay (14) was performed on 4 ~m sections from formalin-fixed,  paraffin-embedded 
tissue,  as described previously  (13),  using  reagents  commercially  prepared  by Vector 
Laboratories, Burlingame,  CA. A semiquantitative  estimate of p21  expression  was per- 
formed by serially diluting  the primary antibody and determining the terminal  dilution 
eliciting  a  1+ reaction in the immunoperoxidase assay (i.e., a definite positive staining 
reaction above background levels). A reference slide exhibiting  a 1  + reaction was used to 
score intensity of staining. Statistical analysis of anti-p21 titres in different histopathological 
groups was performed using a student's t test. 
Results 
Pattern  of staining.  The  transitional  epithelium  of the normal  adult human 
bladder  has  3-7  layers,  the  most  superficial  layer  composed  of large,  often 
multinucleated cells (umbrella cells). Immunoperoxidase staining of sections from 
normal bladder biopsies (obtained from transurethral  resections of the prostate) 
from  six  patients  without  carcinoma  demonstrated  weak staining  of only  the 
most superficial cells (Fig.  1). This pattern of staining was not an "edge" artifact, 
since use of a number of melanoma-specific monoclonal antibodies as the primary 
antibody gave negative results. All bladder epithelial cells not in the superficial 
layer, as well as connective tissue  cells, vascular  endothelial  cells,  muscle, and 
nerve cells were easily identified in sections from the bladder and surrounding 
tissues, and were consistently negative. In the three biopsies showing hyperplasia 
(increase in cell layers without significant nuclear abnormalities),  the pattern  of 
p21  staining was identical  to that seen in the normal  bladder.  Bladder biopsies 
from two patients  with benign  squamous metaplasia of the bladder epithelium 
were negative for p21, also. Sections from  14 biopsies demonstrated moderate 
to marked epithelial  dysplasia, and were uniformly positive for p21  expression 
(Fig.  1). All five specimens showing carcinoma in situ were markedly positive for 
p21  staining  (Fig.  1).  Grade  I  papillary  carcinomas  have  a  normal  epithelial 
structure, and the four specimens examined had a staining pattern similar to that 
seen  in  the  normal  urothelium.  Higher  grade  malignancies  demonstrated  a 
uniformly intense staining for p21 throughout all sections examined, even when 
high  dilutions  of the primary antibody were used.  Pelvic wall metastases from 
two  patients  with  invasive  grade  III  carcinoma  were  also  studied.  In  both 
instances,  the metastases had a similar staining intensity as the primary tumor. 
In contrast to previous studies of colon carcinoma,  minimal  tumor cell hetero- 
geneity of p21  expression was noted (13). One exception to this general pattern 
of p21  staining in grade III carcinomas was found in sections from an invasive, 
markedly anaplastic bladder carcinoma.  Multiple sections demonstrated hetero- 
geneity of p21  staining  with  some  neoplastic  cells scoring  negative  (Fig.  1 E). 
There  was considerable  necrosis  in  this  area  of the  tumor,  and  we could not 
determine  whether  the heterogeneity  of p21  expression was related  to tumor 
cell viability, or was a  reflection of the  heterogeneity of tumor cell expression 
found with other tumor-associated phenotypic markers (15). 
When sections from high  grade carcinomas exhibiting positive immunohisto- 
chemical reactions were not counterstained with hematoxylin, p21-specific stain- 
ing was either  cytoplasmic, or clearly  localized to the  plasma membrane  (Fig. 
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FIGURE  1.  lmmunoperoxidase staining of bladder biopsy sections for ras p21. The primary 
antibody,  RAP-5,  was used  at a  dilution  of 1:1,000.  The dark color represents  a  positive 
reaction of the diaminobenzadine substrate.  All panels except F were lightly counterstained 
with hematoxylin.  A, normal urothelium; B, carcinoma in situ; C, grade I papillary carcinoma; 
D,  grade I11  papillary  carcinoma;  E,  heterogeneity of p21  staining  in markedly  anaplastic 
bladder carcinoma;  F, plasma membrane staining of grade Ili papillary carcinoma,  no hemo- 
toxylin counterstain.  All panels magnification  250 X. 
localized  p21  to  the  inner  surface  of  the  plasma  membrane  (16).  Control 
melanoma-specific antibodies  did not react with sections of bladder carcinomas. 
Quantitation of  p21 Staining.  We used serial dilutions of anti-p21  to determine 
endpoint  titers  on  sections  from  bladder  biopsies  diagnosed  as normal,  hyper- 
plastic,  dysplastic, and carcinoma (Fig.  2).  There  were no significant differences 
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FIC.URE 2.  p21  antigen in benign lesions and bladder carcinomas of different histological 
grades.  Anti-p21  titers were  determined in an immunohistochemical assay as  described in 
Methods. Bar is mean value. Carcinoma in situ (open circles) and hyperplasia (crosses) are also 
noted. 
carcinomas. Both groups had mean titers greater than twofold higher than those 
found with  normal,  hyperplastic, and  grade I  carcinoma sections (P <  0.01). 
Grade II carcinomas tended to titer in an intermediate position between grade I 
and III lesions. 
Discussion 
The normal superficial bladder epithelial cells that express p21  antigen are a 
nondividing population of cells that arise from the basal cell layer and migrate 
toward the surface layer, many fusing and eventually covering the epithelial cell 
surface (17). Thus,  in  contrast to  results  of in  vitro  studies of cellular K-ras 
expression (18),  and studies examining H-ras expression in  regenerating liver 
cells (19), p21 expression in the normal bladder epithelium is not associated with 
cell division, but appears to be present in a  subpopulation of terminally differ- 
entiated cells. Increased p21 expression was not detected in hyperplasia or grade 
I papillary carcinomas, two lesions in which there is little or no nuclear anaplasia. 
However,  moderate  to  severe  dysplasia  is  associated  with  an  increased  p21 
expression, similar to that seen in high grade carcinomas. These observations 
support pathological studies which have indicated that invasive carcinoma arises 
from  flat  dysplastic  lesions,  rather  than  low  grade  papillary  carcinomas  (8, 
summarized  in  20).  Since  dysplastic  lesions  exhibited  a  wide  range  of p21 
expression, it may be possible, in future studies of larger numbers of patients, to 
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with severe dysplasia and carcinoma in situ are at greatest risk for developing 
invasive carcinoma. 
High grade carcinomas of the bladder exhibit a more malignant and invasive 
biological behavior, and have a  poorer  prognosis than  carcinomas of a  lower 
grade (21).  Our findings of elevated p21  expression in high grade carcinomas 
suggest that neoplastic cells expressing ras p21  may have a  growth advantage 
over other transformed cells, and a population of  neoplastic cells expressing high 
levels of this oncogene product may evolve in more aggressive tumors. 
These  studies  do  not  address  whether  the  elevated  levels  of p21  we  are 
detecting are products of a  mutated ras gene. Although the original transfor- 
mation gene isolated from the T24  bladder carcinoma line had a  Gly ~  Val 
substitution of H-ras-1  p2 I, this mutation was not found in  17 primary bladder 
carcinomas (9).  Further, DNA from only 2  of 21  primary high grade bladder 
carcinomas scored positive in the mouse 3T3  transformation system, an assay 
which  appears  to  have  a  bias  for  detecting  ras  p21  mutated at  amino  acid 
positions 12 and 61. Because we found that all high grade carcinomas examined 
expressed increased p21  antigen, it is likely that we are detecting the product of 
an unaltered cellular ras gene. 
Summary 
ras oncogene p21  antigen is present in the most superficial cells of the normal 
bladder  urothelium, as  demonstrated by  immunohistochemical staining.  The 
pattern and intensity of p21  staining of cells  in epithelial hyperplasia and low 
grade bladder carcinoma were similar to that seen in the normal urothelium. In 
contrast,  epithelial cells  in  "premalignant" (dysplastic) lesions and high grade 
carcinomas exhibited an intense staining reaction for p21  antigen, ras p21  may 
be a useful marker for the malignant potential of both premalignant lesions and 
carcinomas of the bladder. 
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